REPORT ABUSIVE REPLY
|
Message Subject
|
Covid19/2021-22 OMICRON/ VIRUS "IHU" FRANCE:P13310/NEWEST VIRUS: "NEOCOV" HIGH INFECTION RATE+1 IN 3 DIE !?! P13315
|
Poster Handle
|
S-man |
Post Content
|
February 9th. (WHERE IS THE EMERGENCY USE AUTHORIZATION??) [ link to www.ox.ac.uk (secure)] Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggestsInhaled budesonide reduced the relative risk of requiring urgent care or hospitalisation by 90% in the 28-day study period. Participants allocated the budesonide inhaler also had a quicker resolution of fever, symptoms and fewer persistent symptoms after 28 days. The study also demonstrated that there was a reduction in persistent symptoms in those who received budesonide. [Prof. Bafadhel]: I am encouraged to see the reduction in persistent symptoms at 14 and 28 days after treatment with budesonide. Persistent symptoms after the initial COVID-19 illness have emerged as a long-term problem. Any intervention which could address this would be a major step forward.'
|
|
Please verify you're human:
|
|
Reason for reporting:
|